Lipton Jack W, Tolod Emeline G, Thompson Valerie B, Pei Lin, Paumier Katrina L, Terpstra Brian T, Lynch Kaari A, Collier Timothy J, Sortwell Caryl E
Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45267, USA.
Neuropharmacology. 2008 Oct;55(5):851-9. doi: 10.1016/j.neuropharm.2008.06.062. Epub 2008 Jul 4.
The current study examined whether modest concentrations of MDMA could increase the survival and/or neurite outgrowth of fetal midbrain dopamine (DA) neurons in vitro since increased DA neurite outgrowth has been previously observed in vivo from prenatal exposure. MDMA concentrations in fetal brain were quantified to determine relevant in vivo concentrations to employ in vitro. A dose response study in vitro demonstrated that MDMA, at concentrations observed in vivo, resulted in increased, DA-specific, neuron survival. Higher doses resulted in non-specific neurotoxicity. MDMA application immediately after culture establishment resulted in greater survival than delayed application, however both were superior to control. MDMA significantly increased the expression of the slc6a3 gene (dopamine transporter; DAT) in culture. Co-application of the DAT reuptake inhibitor methylphenidate (MPH) with MDMA attenuated this effect. Progressive reductions in MPH concentrations restored the MDMA-induced survival effect. This suggests that MDMA's action at DAT mediates the survival effect. Neurite density per neuron was unaffected by MDMA in vitro suggesting that MDMA promotes DA neuron survival but not neurite outgrowth in culture. Finally, animals prenatally exposed to MDMA and examined on postnatal day 35 showed an increase in tyrosine hydroxylase-positive (TH+) neurons in the substantia nigra but not in the ventral tegmental area. These data suggest that during development, MDMA can increase the survival of DA neurons through its action at its transporter. Understanding how MDMA increases DA neuron survival may provide insight into normal DA neuron loss during development.
由于先前在体内观察到产前接触摇头丸会使多巴胺(DA)神经元的神经突生长增加,因此本研究检测了适度浓度的摇头丸是否能提高体外培养的胎儿中脑DA神经元的存活率和/或神经突生长。对胎儿大脑中的摇头丸浓度进行了量化,以确定用于体外实验的相关体内浓度。体外剂量反应研究表明,在体内观察到的浓度下,摇头丸可提高DA特异性神经元的存活率。更高的剂量会导致非特异性神经毒性。培养建立后立即应用摇头丸比延迟应用能带来更高的存活率,不过两者都优于对照组。摇头丸显著增加了培养物中slc6a3基因(多巴胺转运体;DAT)的表达。DAT再摄取抑制剂哌醋甲酯(MPH)与摇头丸共同应用可减弱这种作用。MPH浓度的逐步降低恢复了摇头丸诱导的存活效应。这表明摇头丸在DAT上的作用介导了存活效应。体外实验中,每个神经元的神经突密度不受摇头丸影响,这表明摇头丸促进了培养物中DA神经元的存活,但没有促进神经突生长。最后,产前接触摇头丸并在出生后第35天进行检查的动物,黑质中酪氨酸羟化酶阳性(TH +)神经元增加,但腹侧被盖区没有增加。这些数据表明,在发育过程中,摇头丸可通过其在转运体上的作用增加DA神经元的存活。了解摇头丸如何增加DA神经元的存活可能有助于深入了解发育过程中正常DA神经元的损失情况。